A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
about
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyPharmacological Approaches for Treatment-resistant Bipolar DisorderHaloTag technology: a versatile platform for biomedical applicationsCabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicityDopaminergic therapy in aphasiaEffect of dopamine therapy on nonverbal affect burst recognition in Parkinson's disease.Pramipexole effects on startle gating in rats and normal menDopamine-2 receptor activation suppresses PACAP expression in gonadotrophsBinding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457.Continuous drug delivery in Parkinson's disease.Brain serotonin transporter binding in non-depressed patients with Parkinson's disease.Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes.Dopamine modulates the neural representation of subjective value of food in hungry subjects.Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.Bromocriptine in type 2 diabetes mellitusRotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label studyApo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism.Effects of acute pramipexole on male rats' preference for gambling-like rewards II.The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.Defining the boundaries of the response of sleep leg movements to a single dose of dopamine agonist.Dopamine modulates risk-taking as a function of baseline sensation-seeking trait.Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive.Dopaminergic influences on emotional decision making in euthymic bipolar patientsBaseline Perfusion Alterations Due to Acute Application of Quetiapine and Pramipexole in Healthy Adults.Dopamine Modulates Adaptive Prediction Error Coding in the Human Midbrain and Striatum.Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.Possible sites of therapeutic action in restless legs syndrome: focus on dopamine and α2δ ligands.Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.ADMET considerations for restless leg syndrome drug treatments.Anti-Parkinson's disease drugs and pharmacogenetic considerations.The role of dopamine receptors in the neurotoxicity of methamphetamine.Current treatment options for hyperprolactinemia.Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.
P2860
Q26738349-AF8197F9-B806-4E69-B41B-637D7B99B21CQ26783002-FE48F484-3183-4214-9064-C3B911298286Q26997400-01AB159D-F59C-4967-9EBA-FD8F0F5F5742Q28539553-F3AB5D8C-EC63-4247-A6F7-A9CB3FFA2E4EQ28655767-ACE3A870-AD9A-4138-8549-540D43FFA4C7Q30441215-42F2AB9C-5C8C-436F-9245-07BDD6A79F3AQ30487682-37BD8569-5F21-437E-B02B-B02B1DFC2570Q33765532-89EAB203-2866-437F-A738-9D497CAE899AQ33847160-73461B01-CF61-4484-880B-2CCF3133526FQ34390800-4C67730F-774B-4AE3-942F-5111B665322CQ34619565-672C8938-F43A-4567-8DC6-B5B6690562E6Q34620547-F3C4F733-7A6C-4A65-8660-D4D7AB46D6BEQ34664369-7D983440-D179-43D0-B7C6-8971778DF43DQ35006707-BDA43C07-C637-4666-A8CC-6B80A1B76B3BQ35153082-E8BA2F88-569A-4C89-97A3-3282713B4B22Q35190299-6449194D-6598-48AC-BE0F-F0BECF6EDE01Q35719941-78B67C8D-7AF9-4D17-85EF-601099B45652Q36350266-5D91E95C-2020-4D68-9372-FED67FF71712Q36697929-079793F1-85EA-44C4-B24C-061CB98A0D32Q36777115-831E03BF-60C4-41F5-8E2C-4D8567A3CD01Q36891237-BC1FC8C2-63B3-4DE6-94E3-3AB1D6ECE6E3Q37076311-00E6B85B-0489-4F9C-BEAA-005F0F6643D5Q37106717-876BEDFD-38DC-4A4B-B391-DFDFF1A2A3E4Q37115650-68293B6C-0D47-4CD8-BAEB-4F6F986B160BQ37328780-450FB0BA-8986-4BA6-B178-A8A7D56442DFQ37397793-C615D4B5-DABD-4676-97E9-D994DE38318CQ37409558-F013E6F7-7BDF-462F-81A9-F2E4D53C589EQ37472628-8FDC532E-AF10-478A-9B11-0E80780E67DAQ37658126-B9F0DE58-8AA7-492C-BE72-D5C330931C13Q37776519-481E135F-D97C-4FE8-BDC7-6E3C36CF3CA9Q37895053-A4B632CD-E038-4264-853C-61A92F12BF3FQ37924626-CA917E00-E6DD-45C7-BBC2-AE726F617F8FQ37973462-FF978172-F413-446F-AA7C-C83559B025F4Q38027180-BBB8ECA2-7CFC-47AE-8D50-E8A59EF10FA3Q38097097-FD7C63FC-0CD5-4D9B-A010-35975E3686FEQ38100197-2F68B792-C0D3-4BC2-8571-DF45F2985AFEQ38112205-BE1C0976-0C93-48BD-BE3B-28D5C8566260Q38112589-2A26863C-E793-4FDC-87D4-F7C7826D1ADBQ38189113-3F8AD4F0-A4F5-4104-8EDF-5E37D0160389Q38223072-81A251EC-C8E7-43BE-869F-DA2471DE7344
P2860
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@ast
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@en
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@nl
type
label
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@ast
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@en
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@nl
prefLabel
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@ast
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@en
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@nl
P2093
P3181
P1476
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
@en
P2093
Erich Burger
Sebastian Härtter
Trond Kvernmo
P304
P3181
P356
10.1016/J.CLINTHERA.2006.08.004
P407
P577
2006-08-01T00:00:00Z